# Axon reports Q1 2026 revenue of $807 million, up 34% year over year
Canonical URL: https://biopharmsignal.com/news/AXON/axon-reports-q1-2026-revenue-of-807-million-up-34-year-over-year
Ticker: AXON
Company: Axon Enterprise, Inc.
Source: Axon Enterprise, Inc.
Published: 2026-05-06 20:01 EST
Original Source URL: https://investor.axon.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-06 20:01 EST — [Axon reports Q1 2026 revenue of $807 million, up 34% year over year](https://biopharmsignal.com/news/AXON/axon-reports-q1-2026-revenue-of-807-million-up-34-year-over-year) — Source: Axon Enterprise, Inc.
- 2026-04-22 20:01 EST — [Axon to Release First Quarter 2026 Earnings on May 6, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-first-quarter-2026-earnings-on-may-6-2026) — Source: Axon Enterprise, Inc.
- 2026-04-07 15:00 EST — [Axon Tackles Public Safety's Data Overload With Three New AI Tools](https://biopharmsignal.com/news/AXON/axon-tackles-public-safety-s-data-overload-with-three-new-ai-tools) — Source: Axon Enterprise, Inc.
- 2026-02-24 21:01 EST — [Axon reports Q4 2025 revenue of $797 million, up 39% year over year](https://biopharmsignal.com/news/AXON/axon-reports-q4-2025-revenue-of-797-million-up-39-year-over-year) — Source: Axon Enterprise, Inc.
- 2026-02-10 21:01 EST — [Axon to Release Fourth Quarter 2025 Earnings on February 24, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-fourth-quarter-2025-earnings-on-february-24-2026) — Source: Axon Enterprise, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)